The Muscular Dystrophy Core Center at UCLA is comprised of a group of scientists interested in the development of therapeutics for degenerative muscle disease. The goal of the Center is to improve and facilitate the process of discovery and pre-clinical testing for muscular dystrophy by providing resources, pilot funding and an intellectually rich environment that promotes research progress and encourages productive interactions between muscle researchers and other researchers in related disciplines on campus. The existence of the Center will attract scientists that are both established muscle researchers and those that have not previously conducted muscle research and, with this association, add new expertise and experience to the group. The Cores will use high throughput and non-invasive analyses based on novel cellular assays and novel genetically modified mouse models. The high throughput and non-invasive strategies being used by Center Scientists are not traditionally associated with muscle disease and may thereby foster novel advancements and rapid development of therapeutics. The Center membership reflects a variety of different scientific expertise that will facilitate this endeavor.
The aims of the Administrative Core are to coordinate the activities of the Center and to facilitate these goals. Specifically the Aims of the Administrative Core are:
Aim 1 : To provide administrative support to the Cores and all activities of the Center.
Aim 2 : To facilitate collaboration between Center Scientists and encouragement of Core usage by organizing enrichment activities such as a seminar series, annual retreat and maintenance of a website.
Aim 3 : To oversee review and funding of pilot and feasibility projects.
Aim 4 : To facilitate data sharing and use of the cores from the greater community of dystrophy researchers so that the cores will provide a national resource for muscular dystrophy research.
Muscular dystrophies are a group of devastating neuromuscular disorders with substantial morbidity and premature death. Duchenne MD in particular is the most common, lethal, inherited disorder with an incidence of 1 in 3,000 live male births. Current therapeutic approaches are inadequate and most treatment plans are directed at palliative care. The focus of this Core Center is to use cutting edge, highthroughput assays to identify new therapeutic strategies.
Showing the most recent 10 out of 71 publications
